Evaluation of the Physicochemical and Thermal Properties of the Biofield Energy Healing Treated Ofloxacin

Journal: Journal of Pharmacy and Pharmaceutics PDF  Web

Published: October 5, 2018 Volume: 5 Issue: 2 Pages: 80-87

DOI: 10.15436/2377-1313.18.1965 ISSN: 2377-1313

Authors: Alice Branton, Mahendra Kumar Trivedi, Dahryn Trivedi, Gopal Nayak, Snehasis Jana

Citation: Alice, B., et al. Evaluation of the Physicochemical and Thermal Properties of the Biofield Energy Healing Treated Ofloxacin. (2018) J Pharm Pharmaceutics 5(2): 80- 87.

  • 2231 Views
  • 1285 Downloads

Abstract

Ofloxacin is a broad-spectrum antibiotic useful for the treatment of many Gram-positive and Gram-negative bacterial infections. The objective of this research work was to evaluate the impact of the Trivedi Effect® on the physicochemical and thermal properties of ofloxacin using modern analytical techniques. The sample was divided into two parts. One part of ofloxacin was considered as the control sample (no biofield energy treatment was provided), whereas the second part was received the Biofield Treatment remotely by a famous Biofield Energy Healer, Alice Branton and was termed as the treated sample. The PXRD peak intensities and crystallite sizes were significantly altered ranging from 7.45 % to 73.06 % and -44.1 % to 77.95 %, respectively in the treated sample compared to the control sample. The particle size values were significantly altered at d10 (-19.47 %), d50 (1.14 %), d90 (-8.70%), and D (4, 3) (-10.20%); whereas, the specific surface area was significantly increased by 15.66 % in the treated sample compared to the control sample. The latent heat of fusion and latent heat of decomposition of the treated ofloxacin were significantly increased by 16.24 % and 88.03 %, respec-tively compared with the control sample. The total weight loss was significantly decreased by 6.21 %; additionally, the residue amount was significantly increased by 47.16 % in the treated ofloxacin compared with the control sample. Thus, the Trivedi Effect® might generate a new polymorphic form of ofloxacin which would be more soluble, bioavailable, and be thermally more stable compared with the untreated sample. The Biofield Treated ofloxacin would be more efficacious against urinary tract infections, infections of the urethra and cervix, infectious diarrhoea, pneumonia, cellulitis, chronic bronchitis, prostatitis, plague, etc.

Conclusion

The Trivedi Effect®-Consciousness Energy Healing Treatment has shown a significant effect on the crystallite size, particle size, surface area, and thermal properties of the treated ofloxacin. The PXRD data reported that all the peak intensities of the Biofield Energy Treated ofloxacin were significantly decreased from 7.45 % to 73.06 % compared to the control sample. Similarly, the crystallite sizes of the Biofield Energy Treated sample were sig-nificantly altered ranging from -44.1 % to 77.95 % compared to the control sample. The particle size values in the biofield energy treated ofloxacin were significantly decreased at d10, d90, and D (4, 3) by 19.47 %, 8.70 %, and 10.20 % respectively, whereas slightly increased at d50 by 1.14 compared to the control sample. The specific surface area of the biofield energy treated ofloxacin was significantly increased by 15.66 % compared to the control sample. The DSC data revealed that the ?Hfusion and ?Hdecomposition in the biofield energy treated ofloxacin were sig-nificantly increased by 16.24 % and 88.03 %, respectively com-pared with the control sample. The total weight loss was signifi-cantly decreased by 6.21 %; therefore the residue amount was significantly increased by 47.16 % in the biofield energy treated ofloxacin compared with the control sample. Thus, the Trivedi Effect®-Consciousness Energy Healing Treatment might lead to generate a new polymorphic form of ofloxacin which would be more soluble, bioavailable, and thermally stable compared with the untreated sample. The Trivedi Effect®- Consciousness Ener-gy Healing Treated ofloxacin would be very useful in designing better pharmaceutical formulations that might offer better thera-peutic response against urinary tract infections, infections of the urethra and cervix (i.e., gonorrhea), infectious diarrhoea, pneu-monia, cellulitis, chronic bronchitis, prostatitis, plague, multi-drug-resistant tuberculosis, bacterial infection of the eye and ear, otitis media when there is a hole in the eardrum, etc.